Turner Financial Group Inc. Makes New Investment in ARK Genomic Revolution ETF $ARKG

Turner Financial Group Inc. bought a new stake in ARK Genomic Revolution ETF (BATS:ARKG) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 38,834 shares of the company’s stock, valued at approximately $1,633,000. ARK Genomic Revolution ETF accounts for 1.6% of Turner Financial Group Inc.’s investment portfolio, making the stock its 12th biggest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. Continuum Advisory LLC acquired a new position in shares of ARK Genomic Revolution ETF during the 2nd quarter worth about $76,000. MBA Advisors LLC acquired a new stake in ARK Genomic Revolution ETF in the 2nd quarter worth about $270,000. SkyOak Wealth LLC acquired a new stake in ARK Genomic Revolution ETF in the 2nd quarter worth about $213,000. Beacon Financial Advisory LLC purchased a new stake in ARK Genomic Revolution ETF during the 2nd quarter worth approximately $245,000. Finally, Nwam LLC increased its stake in ARK Genomic Revolution ETF by 55.3% during the 2nd quarter. Nwam LLC now owns 31,704 shares of the company’s stock worth $1,333,000 after buying an additional 11,294 shares in the last quarter.

ARK Genomic Revolution ETF Price Performance

Shares of ARK Genomic Revolution ETF stock opened at $47.14 on Friday. The business has a 50 day simple moving average of $43.03 and a two-hundred day simple moving average of $34.74. ARK Genomic Revolution ETF has a 12 month low of $24.60 and a 12 month high of $50.53.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.